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Introduction: Progression of joint destruction in rheumatoid arthritis (RA) is partly heritably; 45 to 58% of the
variance in joint destruction is estimated to be explained by genetic factors. The binding of RANKL (Receptor
Activator for Nuclear Factor κ B Ligand) to RANK results in the activation of TRAF6 (tumor necrosis factor (TNF)
receptor associated factor-6), and osteoclast formation ultimately leading to enhanced bone resorption. This bone
resorption is inhibited by osteoprotegerin (OPG) which prevents RANKL-RANK interactions. The OPG/RANK/RANKL/
TRAF6 pathway plays an important role in bone remodeling. Therefore, we investigated whether genetic variants in
OPG, RANK, RANKL and TRAF6 are associated with the rate of joint destruction in RA.
Methods: 1,418 patients with 4,885 X-rays of hands and feet derived from four independent data-sets were studied.
In each data-set the relative increase of the progression rate per year in the presence of a genotype was assessed.
First, explorative analyses were performed on 600 RA-patients from Leiden. 109 SNPs, tagging OPG, RANK, RANKL
and TRAF6, were tested. Single nucleotide polymorphisms (SNPs) significantly associated in phase-1 were genotyped
in data-sets from Groningen (Netherlands), Sheffield (United Kingdom) and Lund (Switzerland). Data were
summarized in an inverse weighted variance meta-analysis. Bonferonni correction for multiple testing was applied.
Results: We found that 33 SNPs were significantly associated with the rate of joint destruction in phase-1. In
phase-2, six SNPs in OPG and four SNPs in RANK were associated with progression of joint destruction with
P-value <0.05. In the meta-analyses of all four data-sets, RA-patients with the minor allele of OPG-rs1485305
expressed higher rates of joint destruction compared to patients without these risk variants (P = 2.35x10−4).
This variant was also significant after Bonferroni correction.
Conclusions: These results indicate that a genetic variant in OPG is associated with a more severe rate of joint
destruction in RA.Introduction
Rheumatoid Arthritis (RA) is an autoimmune disorder
that affects 0.5-1% of the population and is associated
with significant morbidity, disability and costs for society.
Radiographic joint destruction reflects the cumulative bur-
den of inflammation and is conceived as an objective
measure of RA severity [1]. The degree of joint destruction
varies significantly between patients. The processes behind* Correspondence: r.knevel@lumc.nl
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reproduction in any medium, provided the orthis difference are incompletely understood. Inflammatory
markers and auto-antibodies are known risk factors for
joint destruction but explain approximately 30% of the
total variance in joint destruction [2]. A twin study sug-
gested that genetic factors influence the severity of joint
destruction in RA and a recent study in the Icelandic RA-
population estimated the heritability of the rate of joint
destruction around 45-58% [3,4]. Hence, to increase the
understanding of progression mediating disease processes,
it seems valuable to study genetic variants that could pre-
dispose to joint destruction in RA.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crucial for healthy bone and is disturbed in systemic or
local conditions that affect the skeleton such as osteo-
porosis or RA. Figure 1 schematically depicts the OPG/
RANK/RANKL/TRAF6 pathway which mediates osteo-
clast related bone loss. RANKL (Receptor Activator for
Nuclear Factor κ B Ligand) is expressed and released by
osteoblasts and activated T lymphocytes [5]. RANKL pro-
motes osteoclast formation and perpetuate their function
and survival through binding of RANK (Receptor Activa-
tor of Nuclear Factor κ B). Subsequently, the signal of
RANK is mediated by TRAF6, a member of the TNF re-
ceptor associated factor (TRAF) protein family, which
functions as a signal transducer in the NF κ β family [6].
The process of osteoclast formation and bone resorption
is also regulated by OPG (osteoprotegerin), which is se-
creted by osteoblasts. By binding of OPG to RANKL, acti-
vation of the RANK receptor is inhibited.
The net bone loss in RA suggests that there is an imbal-
ance in the OPG-RANKL axis favoring bone resorption
and resulting in erosions [6-8]. Recent studies showed that
in RA RANKL is, amongst others, expressed in cultured
synovial fibroblasts, chondrocytes and by CD4+ and CD8+
T lymphocytes [5,9-11]. In addition, the ratio of OPG/
RANKL serum levels is associated with joint destruction
in RA [12]. Furthermore, several studies have observed an
association of genetic variants in OPG, RANK or RANKL
with bone mineral density and osteoporosis [13-16]. To-
gether, these data led us to hypothesize that genetic vari-
ants in OPG, RANK, RANKL and TRAF6 are associated
with the severity of joint destruction in RA. We tested this
hypothesis using four data-sets of European RA-patients
with longitudinal radiological data on joint destruction.
All data-sets included patients that were diagnosed in aFigure 1 Schematic presentation of the OPG/RANK/RANKL/TRAF6 pat
the binding of RANKL to the extracellular domain of RANK which panes th
leading to the activation of several transcription factors (among which NFκ
differentiation, activation and survival. OPG is able to prevent the interactioperiod when treatment strategies were less aggressive and
disease activity was less controlled than today. These con-
servative treatment strategies made these data-sets suit-




Four data-sets consisting of adult European RA-patients
were studied. RA was defined according to the 1987
ACR criteria in all data-sets except for the Lund data-set
where the 1958 ACR-criteria were used. X-rays of both
hands and feet were available for all patients (Table 1).
All patients gave their informed consent and approval
was obtained from the local Ethical Committee of each
hospital (METC Leiden, EPN Lund, METC Groningen,
COREC Sheffield).
Leiden-early arthritis clinic cohort (Leiden-EAC)
This cohort contained 600 early RA-patients from the
western part of the Netherlands, who were included be-
tween 1993 and 2006 [2]. Arthritis patients were in-
cluded at the first visit at the outpatient clinic and yearly
followed. Blood samples were collected at baseline. DNA
was extracted en preserved for later usage. X-rays were
taken at baseline and on yearly follow-up visits during 7-
years. In total, 2,846 sets of hands and feet X-rays were
available. All X-rays were chronologically scored by one
experienced reader who was unaware of genetic or clin-
ical data using the Sharp-van der Heijde scoring method
(SHS) on hands and feet [17]. This method quantifies
both joint-space-narrowing, a feature of cartilage loss,
and bony erosions. It is a semi-quantitative method, the
maximal total scores is 448. 499 randomly selected X-rayshway in osteoclasts. The RANK signaling cascade is initiated upon
e signal along to TRAF6. The activation of TRAF6 initiates pathways
β and MAP kinase mediators), which contribute to osteoclast
n between RANKL and RANK.
Table 1 Characteristics for each data-set
Cohort Leiden-EAC Groningen Sheffield Lund
(n = 600) (n = 275) (n = 391) (n = 147)
Year of diagnosis 1993-2006 1945-2001 1938-2003 1985-1990
Follow-up years* 7 years 14 years Not applicable* 5 years
Total no. of X-ray sets 2,846 862 391 781
Method of scoring SHS SHS Larsen Larsen
Female n (%) 412 (69) 194 (71) 290 (73) 98 (67)
Age at diagnosis, mean ± SD 56 ± 16 49 ± 13 46 ± 13 51 ± 12
ACPA + n (%) 323 (55) 160 (80) 302 (79) 114 (80)
Rheumatoid factor n (%) 343 (59) 258 (94) N/A* 115 (81)
SHS Sharp-van der Heijde score.
*Data of Leiden-EAC, Groningen and Lund were from baseline onwards during respectively 7, 14 and 5 years of follow-up. The data of Sheffield were collected
once during the disease period, the mean disease duration was 15 years (range 3–65 years).
N/A not available.
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within the reader was 0.91. The treatment of these pa-
tients could be divided into three treatment periods.
Patients included in 1993–1995 were initially treated
with NSAIDs, patients included in 1996–1998 were ini-
tially treated with chloroquine or sulphasalazine and pa-
tients included after 1999 were promptly treated with
methotrexate or sulphasalazine.
Groningen
The second set of data involved 275 RA-patients from the
Northern part of the Netherlands that were diagnosed in
1945–2001. The follow-up duration after diagnosis was
limited to 14-years. The mean number of X-ray sets (hands
and feet) per patient was 3.1 (with a maximum of eight X-
rays per patient). The total number of sets of X-rays was
862. The X-rays were scored chronologically by one of two
readers using SHS. ICCs within readers were >0.90 and be-
tween readers 0.96. The development of joint destruction
was significantly different for patients included after 1990
compared to patients included before 1990. This observa-
tion is in line with the introduction of early initiation of
treatment with Disease Modifying Anti-Rheumatic Drugs
(DMARDs) after 1990.
Sheffield
The third set of patients concerned 391 RA-patients
from the area of Sheffield, UK. RA-patients with X-rays
available were recruited from the Rheumatology depart-
ment of the Royal Hallamshire Hospital in Sheffield
between 1999 and 2006 [17]. RA-patients were assessed
once during their disease course. The mean (±SD) dis-
ease duration at assessment was 15 ± 11 years (range 3–
65 years). X-rays of hands and feet were scored by one
reader using a modification to Larsen’s score [18]. This
method quantifies the severity of bony erosions and joint
space narrowing in one score, both elements are notscored separately. Ten percent of films were scored twice
to quantify the intra-observer variation by a weighted
kappa score which was 0.83 [19].
Lund
This cohort concerned 183 Swedish early RA-patients that
were prospectively followed yearly during 5-years, of which
147 had X-rays and DNA available [18,20]. Patients were
recruited from primary care units in the area of Lund dur-
ing 1985–1989. X-rays of hands and feet were taken at
study start and annually for 5-years, resulting in a total of
781 sets of X-rays. X-rays were scored chronologically ac-
cording to Larsen by one of two readers [21]. The ICC be-
tween the readers determined on 105 X-rays was 0.94. In
the inclusion period, immediate DMARD-therapy was not
common and at 5-years follow-up still a substantial pro-
portion of the patients were not treated with a DMARD.
The most commonly used DMARDs were chloroquine, D-
penicillamin, sodium aurothiomalate and auranofin [22].
SNP selection and genotyping
The region of OPG, RANK, RANKL and TRAF6 plus
the haplotype blocks up- and downstream these genes
were tagged by the algorithm of HaploView [23]. One SNP
in OPG, two in RANK and one in TRAF6 were known to
be amino acid changing SNPs; respectively rs2073618,
rs1805034, rs8092336 and rs3740958. Eight SNPs were
associated with bone mineral density in the hip or spine
in previous studies; OPG rs6993813 [13], rs646980 [13],
rs4355801 [14] and rs2073618 [15]; RANK rs3018362
[13] and rs884205 [16]; RANKL rs9594738 [13] and
rs9594759 [13]. All these SNPs were forced to include.
Pairwise tagging SNPs were selected from the CEPH/
CEU hapmap data-set (phase II, release 21, NCBI
build 35) using haploview software (MAF >0.05, pair-
wise r2 > 0.8). In total 109 SNPs captured OPG (34),
RANK (54), RANKL (21) and TRAF6 (17). Multiplex
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platform, according to the protocols recommended by
the manufacturer [Illumina, San Diego, CA]. Three SNPs
could not be designed; rs10505348, rs7239667 and
rs9951012. Proxies were sought and found for rs10505348:
rs4355801 (r2 = 0.80), for the other two SNPs no good
proxy existed.
Software supplied by Illumina was used to automatic-
ally identify the genotypes. Each 96-wells plate consisted
of 1 positive and 1 negative control, which were all in-
deed tested positive and negative. Clusters were evalu-
ated and all doubtful calls were checked; after manually
evaluating the spectra of each cluster, the genotypes
were accepted, recalled or rejected. At least 12% of the
genotypes were assessed in duplicate, with an error rate
of <2.5% for all SNPs. Genetic sex was checked with the
reported sex in the database. SNPs were selected if the
success rate were ≥95% and the Hardy-Weinberg equi-
librium (HwE) p-value > 0.001.
SNPs that had a clear and significant association with
joint destruction in the first cohort were selected to be
genotyped in the other three data-sets. The SNPs were
genotyped as a part of multiplex SNPs arrays designed
with Sequenom iPLEX, according to the protocols rec-
ommended by the manufacturer [Sequenom, San Diego,
California]. Software supplied by the same manufacturer
was used to automatically identify the genotypes. Two
SNPs could not be designed but full proxies (r2 = 1.0)Figure 2 Schematic depiction of the SNPs selection process. *LD is lin
dataset of phase-1 as calculated with R2 in haploview, or were part of a hawere typed instead (rs17666267:rs9959310 and rs1564861:
rs3134057). Each iPLEX consisted of at least 9 positive
and 9 negative controls, which were indeed tested po-
sitive and negative. All doubtful calls were checked
manually, DNA samples with >30% failed SNPs were ex-
cluded from analysis (n = 31). At least 5% of the geno-
types were assessed in duplicate, with an error rate of <1%.
SNPs were selected if the success rate were ≥95% and
HwE p-value > 0.001.
Statistical analysis
Associations between genotypes and radiographic joint
destruction were analyzed. Two phases were carried out.
An overview of the SNP selection process is provided in
Figure 2. First, an explorative analysis was performed in
the Leiden-EAC. In this data-set the tagged SNPs were
tested in two ways; additively and recessively. Since
phase-1 was an explorative phase no correction for
multiple testing was applied yet and SNPs with a
p-value <0.05 were studied in phase-2.
Significant SNPs from phase-1 were preceded in
phase-2 if they had a high enough minor allele frequency
and if the effect was independent of other SNPs (see
Additional file 1: Table S1). In phase-2 SNPs were ana-
lyzed in three independent data-sets and meta-analyses
of all four data-sets. In the present study the power to
detect genetic effects is a function of the number of pa-
tients and the number of measurements per patientkage disequilibrium, some SNPs were in strong correlation in the
plotype were other SNPs caused the significant association.
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results of phase-1 contained (individually and combined)
less X-rays than the initial data-set. Consequently, the
power to replicate findings in each data-set individually
as well as in the three replication data-sets together was
expected to be limited due to a lower number of X-rays
than in the discovery data-set. Therefore it was decided
to test the SNPs in each data-set separately taking ad-
vantage of the specific data-set characteristics and to
subsequently perform a meta-analysis on the results to
determine the association of the SNPs with the rate of
joint destruction. An inverse variance weighting meta-
analysis testing for fixed effect [26,27] was performed in
Stata, version 10.1. In phase-2 analyses were performed
either additively or recessively depending of the findings
of phase-1. To provide insight into the heterogeneity of
the cohorts the I2 for heterogeneity was calculated.The
choice for a fixed effect model was guided by the argu-
ment of Lebrec et al. [27] that the heterogeneity is of less
importance in genetic studies when the search for a sig-
nificant association in the first studies is of more import-
ance than the magnitude of the effect size. Also large
GWAs on RA susceptibility had used fixed effect models
[28]. In subanalyses a random effect model was also used.
For the analyses in Leiden-EAC, Groningen and Lund
a multivariate normal regression model for longitudinal
data was used with radiological score as response vari-
able (see detailed descriptions elsewhere [29]). Adjust-
ment variables were entered based on their association
with joint destruction; in Leiden-EAC age, gender and
the described treatment periods, in Groningen age and
inclusion ≤/>1990, as proxy for DMARD-therapy and in
Lund adjustments were made for age.
In the Sheffield data-set, each patient had a set of
hands and feet X-rays at one time-point. To make the
scores comparable to the other data-sets, the estimated
yearly progression rate was calculated, by dividing the
total Larsen by the number of disease years at time of X-
ray [30]. The SNP association was tested in a linear re-
gression analysis with log-transformed estimated yearly
progression rate as outcome variable. No adjustments
were applied as none of the tested variables was signifi-
cantly associated with joint destruction.
In all data-sets, the radiological scores were log-
transformed to obtain a normal distribution. Since the
analyses were performed on the log-scale, the resulting
coefficient on the original scale indicates how many fold
the joint destruction increased per year of follow-up.
Over a follow-up period of n years the coefficient in-
creases to the power of n.
Testing multiple SNPs on one data-sets leads to inflation
of the p-value. It is debatable which multiple testing cor-
rection is best to use. In the current study the most con-
servative method was applied, the Bonferroni method, toreduce the chance on false-positive findings as much as
possible. Since phase-1 was used as identification phase,
this correction was applied to the number of variants
tested in phase-2.
Haplotype analyses
Haplotypes in OPG, RANK, RANKL and TRAF6 were
studied. Haplotype blocks for the tag-SNPs were defined
with Gabriel’s method [31]. Haplotypes were assigned to
each individual using PLINK 1.06 requiring a probabil-
ity >0.8. Analyses of the haplotypes were performed
with methods similar to those used for the analyses of
the individual SNPs by now testing the presence of a
haplotype compared to the absence of the haplotype.
Results
Phase-1; SNP identification
123 tagging SNPs in OPG (n = 33), RANK (n = 52),
RANKL (n = 21) and TRAF6 (n = 17) were genotyped.
Eleven SNPs were not analyzed because of a low typing
success rates and three were out of HwE. From the 109
analyzed SNPs, 33 SNPs were significantly associated
with joint destruction (see Additional file 1: Table S1);
eighteen SNPs were located in OPG, ten in RANK, four
in RANKL and one in TRAF6. The associations of OPG
SNPs were most prominent in the additive analyses. For
RANK, RANKL and TRAF6 mainly recessive associations
were observed (see Additional file 1: Table S1). The ef-
fect sizes observed represent the estimated relative pro-
gression rates per year. Consequently over a follow-up of
a certain number of years, the effect sizes increases by
the power of the number of follow-up years. For ex-
ample, the estimate of 1.03 fold rate of joint destruction
per year of the minor variant of OPG-1485305 (T) com-
pared to patients with the common genotypes equals
1.23 (1.03^7) fold rate of joint destruction over 7-years.
In other words patients carrying one minor allele had
over 7-years a 23% higher rate of joint destruction
(Figure 3).
Haplotype analyses were performed in addition to SNPs
analyses. In phase-1, four haplotypes from one haplotype
block in OPG were identified as possible more informative
than the individual SNPs located in these haplotypes (see
Additional file 2: Table S2) To tag these haplotypes in
phase-2, one non-significant SNP of phase-1 was also
typed in phase-2, rs1905785.
Phase-2; meta-analysis
Of the 33 significant SNPs from phase-1 19 were subse-
quently typed and analyzed in phase-2 since they had a
high enough minor allele frequency and their associa-
tions were independent of other SNPs (see Additional
file 1: Table S1 and Additional file 3: Table S3 for de-
tailed information). Therefore these nineteen SNPs plus
Figure 3 Depicted is OPG-rs1485305 in the Leiden-EAC (A) and in the meta-analysis on all data-sets (B). SHS = Sharp-van der Heijde score.
The effect sizes are the estimated relative progression rates per year for the presence of the minor allele for OPG compared to patients without
the minor allele. A) The presence of the minor variant of OPG-1485305 (T) is associated with a 1.03 fold rate of joint destruction per year
compared to patients with the common genotypes in the Leiden-EAC. Since the effect sizes increases by the power of the number of follow-up
years, these patients have a 1.23 (1.03^7) fold rate of joint destruction over 7-years, in other words a 23% higher rate of joint destruction.
B) The meta-analysis is based on a fixed effect model, which is applied to genetic studies to test whether there is statistically significant effect;
generalizability of the effect is of less importance. Consequently, this method is less suitable to estimate the effect size overall. Therefore, the
estimated effect of the meta-analysis is depicted in gray. The I2 was 13.6% and the p-value for heterogeneity was 0.325. The p-value for a random
model was 0.004 and the effect size 1.23 (see also Additional file 3: Table S3).
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phase-2. As expected due to insufficient power of the
replication cohorts, the 95% confidence intervals in
each of the three cohorts separately all included 1 (see
Additional file 3: Table S3). The SNPs were subse-
quently analyzed in all 1,418 patients in an inverse
variance weighting meta-analysis. Here, ten SNPs (six
located in OPG and four in RANK) were significantly
associated with rate of joint destruction (0.04 > P >
2.4×10−4). After correction for testing 20 SNPs using
the Bonferroni method, one SNP was significantly asso-
ciated with the rate of joint destruction; OPG-r1485305
(Figure 3). Patients carrying at least one minor allele of
OPG-rs1485305 (T) had a higher rate of joint destruc-
tion as compared to patients without this minor allele
(P = 2.35×10−4,uncorrected P-value).
When the association of OPG-rs1485305 with the rate
of joint destruction was studied in ACPA-negative and
ACPA-positive patients separately in the Leiden-EAC,rs1485305 was significantly associated with progression
of joint destruction in ACPA-negative patients (1.29 95%
CI 1.10-1.50, P = 0.001) but not in ACPA-positive patients
although a similar trend was observed (1.14 95% CI 0.97-
1.34, P = 0.11). Also when the analysis in the total group of
RA –patients was adjusted for ACPA and rheumatoid
factor the association remained significant (1.20 95% CI
1.07-1.35, P = 0.02). Similarly, adjusting for the level of in-
flammation measured by C-reactive protein levels at base-
line) did not affect the effect size and significance was
maintained (1.29 95% CI 1.14-1.46, P = 0.0005). This sug-
gests that the association between OPG-rs1485305 and
radiological progression in the Leiden data was not con-
founded by auto-antibodies or CRP-levels. Unfortunately,
our data on these adjustment factors were too limited to
confirm this with the other cohorts.
In phase-2, none of the tested haplotypes provided
additional information to the results of the individual
SNPs (see Additional file 2: Table S2).
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The variance in joint destruction between RA-patients is
considerable and the mechanisms driving these differences
are thus far scarcely understood. Part of the severity of
joint damage is explained by the cumulative levels of in-
flammation [32] though this explanation is incomplete. We
reasoned that individual susceptibility of bones to erode
may affect the severity of joint destruction in RA as well.
We therefore studied the association of genetic variants in
OPG, RANK, RANKL and TRAF6 with joint destruction as
the products of these genes together constitute a pathway
that is crucial in osteoclastogenesis and bone resorption.
One SNP, OPG-rs14085305, was observed to significantly
associate with progression of joint destruction in RA.
The association between OPG-rs14085305 with progres-
sion of joint destruction in RA was independent of auto-
antibody positivity. However, after stratification for ACPA
the association was only significant in the ACPA-negative
group. This seemingly counterintuitive result could be
explained by a strong effect of the association in the
ACPA-negative group, by which the multivariable analysis
remained significant. Furthermore, since the effect sizes
iwere quite similar in the ACPA-positive and ACPA-
negative subgroups, it is also possible that the association
in ACPA-positive patients was insufficiently powered
to obtain statistical significance in this subgroup. Larger
datasets of ACPA + RA-patients would be required to
further elucidate the association between rs14085305
and joint damage progression in ACPA + RA.
OPG is expressed in several cells and tissues among
which osteoblasts, chondrocytes and bone marrow. Serum
OPG is decreased in the synovium and serum of RA-
patients [33]. Low serum OPG/RANKL ratio’s have been
associated with progression of joint destruction [12]. In
addition, low OPG/RANKL ratio’s in cartilage are associ-
ated with the degree of joint destruction is situated in the
5-UTR flanking region of OPG. Thus far no functional
data on this variant exist, hence the mechanism by which
rs1485305 affects OPG expression or function is yet un-
known. Nonetheless, OPG-rs1485305 was recently also
observed to associate with bone mineral density loss,
which strengthens the relevance of this SNP in relation to
bone and joint disease [34].
Our group recently performed a genome-wide study on
joint damage progression in ACPA-positive RA-patients
[35] and evaluated the genetic variants included on the
Immunochip in relation to joint damage progression in RA
[36]. In these studies the current variant OPG-rs1485305
was not identified as a risk factor for joint damage progres-
sion as this variant was not (also no proxies with r2 > 0.80)
included in both these genotyping platforms.
An advantage of the four studied data-sets is that the
evaluated RA-patients were treated in an era when treat-
ment was not as aggressive as nowadays. Hence, theradiologic progression rates of the studied patients are
more reflective of the natural course of RA than that of re-
cently treated patients. Some data-sets included patients
from different periods that had received different treat-
ment regiments potentially affecting an association with
progression of joint destruction. Since treatment may be
an effect modifier masking associations with radiological
progression, the analyses in these data-sets were adjusted
for inclusion period as proxy for treatment.
Replication data-sets are ideally larger than the initial
data-set, since effects sizes are generally smaller at a repli-
cation stage. A limitation of the present study is that we
were not able to include replication data-sets that con-
tained more X-rays than the initial data-set and of which
the RA-patients were “conventionally” treated. Most likely,
few of such longitudinal data-sets exist. In one data-set
only one radiograph per patient was available; it is known
that this results in less precise estimations of the progres-
sion rate compared to having serial radiological measure-
ments [37]. This was here also depicted by a broader
confidence interval of the effect estimate of the Sheffield
data. Nonetheless the results of a meta-analysis on
rs1485305 without the Sheffield data was still signifi-
cant (p = 0.0024 data not shown).
Since the number of patients and the number X-rays of
each data-set separate were insufficient to allow well pow-
ered analyses, the data of the different replication cohorts
were summarized in inverse variance weighting meta-
analyses. Notably, also the replication data-sets combined
contained less radiological measurements than in phase-1.
Importantly, the effects of OPG-rs1485305 went into the
same direction in each dataset supporting the validity of
the results. In addition, the heterogeneity (I2) of the data
for OPG-rs1485305 was only 13.6%, making it less likely
that OPG-rs1485305 is a false positive finding due to dif-
ferences between the four cohorts. This I2 supports the
use of a fixed effects meta-analysis, but also when a ran-
dom effect model was used OPG-rs1485305 remained sig-
nificant (Additional file 3: Table S3).
To further prevent false positive findings due to per-
forming multiple comparisons, data were corrected for
multiple testing using the Bonferroni method. This was
done in phase-2, since phase-1 was used as discovery
phase. However, the association of OPG-rs1485305 with
the rate of joint destruction would also have remained sig-
nificant when Bonferroni correction would have been ap-
plied in phase-1 correcting for 109 SNPs. This further
consolidates the validity on the results on OPG-rs1485305.
Interestingly, several other studies, among which
genome-wide association studies, have revealed several
genetic variants in RANKL/RANK/OPG to associate with
bone mineral density or osteoporosis. Therefore during
the tagging and SNP selection phase, such variants were
forced into the selection. Interestingly (except for
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ated with progression of joint destruction in phase-2. Con-
ceptually, the balance between osteoblast and osteoclast
activity is crucial both in osteoporosis and joint destruction
in RA but the individual genetic variants predisposing to
such systemic or local bone loss are largely dissimilar.
During the SNP selection phase, three coding SNPs
were also prioritized; these three were also not signifi-
cantly associated after correction for multiple testing in
phase-2. A coding variant in RANK, rs8092336, was sig-
nificantly associated with joint destruction in phase-1
and phase-2, but did not remain significant after correc-
tion for 20 tests. The same was observed for a coding
SNP in OPG, rs2073618, which has also been associated
with bone mineral density [15]. These two SNPs could
potentially be associated with progression of joint de-
struction, but the chance of a Type-I error is too large to
conclude this on the basis of current data.
Finally, TRAF6 was chosen as candidate gene because it
is a relevant signal transducer in the Nuclear Factor κ B
pathway. Rs540386 in TRAF6 was previously also identi-
fied as a risk locus for RA susceptibility, though TRAF6
was not genome-wide significant in a recent study on
more than 11,000 cases and 15,000 controls [29,38]. Our
candidate gene study had started a year before the first re-
port of TRAF6 and RA susceptibility was published, hence
this report had not affected the choice of TRAF6 as candi-
date gene. The susceptibility SNP rs540386 is in close LD
(r2 = 0.94) with one of the tag SNP evaluated in the
current study (rs11033647). This SNP was not associated
with the rate of joint destruction in our analyses. Although
this could be a false-negative finding, it is also possible
that different genetic variants are involved in RA-
susceptibility and the progression of joint destruction.
The current study included patients only. Whether the
rs1485305 is also relevant for RA-susceptibility was not
studied here. Nonetheless, several genome-wide studies
have been performed on RA-susceptibility and >40 genetic
susceptibility factors have been identified but rs1485305 in
OPG was not one of them. Presumably different genetic
factors are involved in developing RA and in progression
of structural damage.
In conclusion, with a candidate gene approach evaluat-
ing patients of four different cohorts, we found association
of a genetic variant in OPG with an increased rate of joint
destruction in RA. The present data support the role of
OPG in joint destruction in RA by indicating that the risk
allele of rs1485305 may affect the homeostasis in bone.Additional files
Additional file 1: Table S1. Results of SNP analysis phase-1 in the
Leiden-EAC.Additional file 2: Table S2. Haplotype analyses.
Additional file 3: Table S3. Results of the significant SNPs of the
phase-I, phase-II and the meta-analysis (fixed as well as random effects).
The fixed effect model was our main model of choice, guided by the
argument of Lebrec et al. [27] that the heterogeneity is of less
importance in genetic studies when the search for a significant
association in the first studies is of more importance than the magnitude
of the effect size. To provide insight into the heterogeneity of the cohorts
the I2 for heterogeneity was calculated. In this table also the results of
a random meta-analysis is provided. The final conclusion that
OPG-rs1485305 is significantly associated with rate of joint destruction is
irrespective of which model for meta-analysis is used.
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